The maintenance of serological memory requires the maturation of naive B cells into memory B cells and long-lived plasma cells 1 . This involves interactions between ligand-receptor pairs that include CD40 ligand and the costimulatory molecule CD40; the B cell-activation factor BAFF or the proliferation-inducing ligand APRIL and the transmembrane activator TACI or the B cell maturation antigen BCMA; and Toll-like receptor (TLR) ligands and TLRs. In addition, it involves the transcription factor STAT3. Ligation of TLR9 on naive B cells promotes proliferation, immunoglobulin secretion and maturation into memory B cells [2] [3] [4] and acts in synergy with CD40 and TACI in causing B cell activation 5, 6 . The TLR9 ligand CpG oligodeoxynucleotide (ODN) is an adjuvant for antibody responses in mice 7, 8 . Defective B cell responses to ligation of TLR9 have been observed in patients with common variable immune deficiency characterized by poor antibody production and less generation of memory B cells and plasma cells 9 .
A r t i c l e s
The maintenance of serological memory requires the maturation of naive B cells into memory B cells and long-lived plasma cells 1 . This involves interactions between ligand-receptor pairs that include CD40 ligand and the costimulatory molecule CD40; the B cell-activation factor BAFF or the proliferation-inducing ligand APRIL and the transmembrane activator TACI or the B cell maturation antigen BCMA; and Toll-like receptor (TLR) ligands and TLRs. In addition, it involves the transcription factor STAT3. Ligation of TLR9 on naive B cells promotes proliferation, immunoglobulin secretion and maturation into memory B cells [2] [3] [4] and acts in synergy with CD40 and TACI in causing B cell activation 5, 6 . The TLR9 ligand CpG oligodeoxynucleotide (ODN) is an adjuvant for antibody responses in mice 7, 8 . Defective B cell responses to ligation of TLR9 have been observed in patients with common variable immune deficiency characterized by poor antibody production and less generation of memory B cells and plasma cells 9 .
After binding its ligand, TLR9 associates with and signals via the adaptor MyD88 (ref. 10) . Resting B cells express several TLRs, including TLR4 in mice, and TLR6, TLR7, TLR9 and TLR10 in mice and humans. MyD88 is important for antibody responses to T celldependent antigens administered with lipopolysaccharide (LPS) or CpG as the adjuvant [11] [12] [13] , although exceptions have been noted 14 . MyD88 does not seem to be involved in the antibody response to T cell-dependent antigens administered with alum as adjuvant, or certain bacterial antigens [15] [16] [17] , but is important for the antibody response to viruses 12, 18, 19 .
DOCK8 is one of 11 members of the DOCK180 superfamily 20 . DOCK (dedicator of cytokinesis) proteins have characteristic DOCKhomology region 1 (DHR-1) and DHR-2 domains. The DHR-1 domain is important for targeting DOCK proteins to membranes through its binding of phosphatidylinositol-(3,4,5)-triphosphate 21 . The DHR-2 domain binds to GTPases of the Rac-Rho family and can function as an exchange factor for these GTPases 21 . The biological functions of DOCK8 include the regulation of cell migration, morphology, adhesion and growth 20 . A mouse genetic screen for mutations that disrupt the persistence of the antibody response has identified loss-of-function mutations in Dock8 (ref. 22 ). DOCK8-mutant mice have T cell A r t i c l e s lymphopenia, and their B cells do not develop into marginal-zone B cells or persist in germinal centers and undergo affinity maturation. Reconstitution experiments have indicated that DOCK8 expression in B cells is important for the normal persistence of germinal centers 22 , which suggests that DOCK8 expression in B cells has a key role in serological memory.
Mutations of DOCK8 have been shown to account for a combined immunodeficiency in humans characterized by greater susceptibility to viral skin infections, severe allergy, high serum concentrations of immunoglobulin E (IgE), eosinophilia, T cell lymphopenia and impaired antibody responses 23, 24 . We analyzed the response of B cells from DOCK8-deficient patients to the TLR9 ligand CpG. We found that DOCK8 mediated a previously unknown MyD88 signaling pathway essential for TLR9-driven B cell proliferation and immunoglobulin production.
RESULTS

Antibody response and memory B cells in DOCK8 deficiency
We studied ten patients 3.5-15 years of age with homozygous mutations in DOCK8 (Supplementary Table 1 ). None had detectable DOCK8 protein in lysates of peripheral blood mononuclear cells (PBMCs) or Epstein-Barr virus-transformed B cells (EBV-B cells; data not shown). All had typical clinical characteristics of DOCK8 deficiency (Supplementary Table 2 ). Five patients, from whom serum was available before the initiation of immunoglobulin-replacement therapy, had defective IgG antibody responses to tetanus toxoid (TT), vaccine against hepatitis B, TT-conjugated vaccine against Haemophilus influenzae type B or conjugated polyvalent vaccine against pneumococcus ( Table 1) . The IgM antibody response to TT was significantly lower in these patients than in normal children (Supplementary Fig. 1) . Two of these patients, 8 and 15 years of age, mounted a brisk early antibody response 8 weeks after a booster dose of TT, which fell below the protective amount 15 and 12 months later, respectively (Fig. 1a) . This response was in contrast to the >99% of normal children in whom protective antibody titers persisted 5 years after TT booster vaccination 25, 26 .
Flow cytometry of PBMCs showed that the frequency of CD3 + T cells was significantly lower in the patients than in age-matched healthy controls, as reported before 23, 24 , whereas the frequency of CD19 + B cells was normal or greater (Fig. 1b) . There was a considerable deficiency in the frequency of circulating CD19 + CD27 + memory B cells in all patients examined, with CD19 + CD27 − naive B cells accounting for nearly all (>95%) of their B cells (Fig. 1c,d) . The frequency of circulating IgD + CD27 + marginal zone-like B cells was lower in the patients than in the controls (Supplementary Fig. 2) , consistent with the findings obtained with DOCK8-mutant mice 22 . These results indicated that DOCK8 was important for the generation of memory B cells and serological memory in humans.
Impaired B cell activation by CpG in DOCK8 deficiency
The TLR9 ligand CpG ODN 2006 (called 'CpG' here) acts selectively on human B cells 27 and has no detectable effects on non-B cells 28 . PBMCs from DOCK8-deficient patients were considerably deficient in their ability to proliferate and to secrete IgM and IgG in response to stimulation with CpG compared with PBMCs isolated from blood from age-matched normal subjects that was shipped together with the patients' blood (Fig. 2a) . In contrast, DOCK8-deficient PBMCs proliferated and secreted IgM normally after stimulation with antibody to CD40 (anti-CD40) plus interleukin 21 (IL-21) and secreted about half the amount of IgG secreted by normal PBMCs (Fig. 2b) . PBMCs from the patients proliferated and secreted IgE in response to anti-CD40 plus IL-4 to an extent similar to that of normal PBMCs (Fig. 2c) .
The considerably impaired response of DOCK8-deficient PBMCs to CpG could not have been explained simply by the lack of memory B cells. Highly purified naive B cells from normal subjects (>95% CD27 − ; Supplementary Fig. 3a ) proliferated in response to CpG to an extent similar to that of total B cells isolated from the same subjects (Fig. 2d) . Consistent with published reports [2] [3] [4] , the concentration of IgM and IgG secreted by CpG-stimulated naive B cells was much lower, at about one-half and about one-third, respectively, of that secreted by CpG-stimulated total B cells (Fig. 2d) . In contrast, DOCK8-deficient purified B cells, which were almost all naive, completely failed to proliferate or to secrete IgM and IgG in response to CpG (Fig. 2d) . Proliferation and secretion of IgM and IgG in response to anti-CD40 Fig. 3b ). The diminished secretion of IgG by DOCK8-deficient PBMCs in response to anti-CD40 plus IL-21 was most probably secondary to the lack of memory B cells, because purified normal naive B cells showed similar less secretion of IgG in response to anti-CD40 plus IL-21 than that of total B cells ( Supplementary Fig. 3b ). The inability of B cells from DOCK8-deficient patients to respond to CpG was not due to more apoptosis and cell death, as determined by staining with annexin V and propidium iodide ( Supplementary Fig. 4 ). These results indicated that B cells from DOCK8-deficient patients had an intrinsic and selective defect in their ability to respond to CpG.
CpG activates known pathways in DOCK8-deficient B cells
The stimulation of B cells with CpG ODN induces the expression of AICDA, which encodes activation-induced cytosine deaminase (AID), critical for isotype switching, and upregulates expression of the low-affinity IgE receptor CD23 and the costimulatory molecule CD86 (refs. 4,29) . Stimulation with CpG induced similar AICDA mRNA expression in PBMCs and B cells from DOCK8-deficient patients and controls ( Fig. 3a) and similarly greater frequency of CD19 + B cells that expressed CD23 and CD86 (Fig. 3b,c) . The mean fluorescence intensity of these antigens was similar for DOCK8-deficient B cells and control B cells (Fig. 3b,c) . 34 . To examine Rac1 activation, we used a fusion of glutathione S-transferase and the GTPase-binding domain of p21-activated kinase to precipitate GTP-bound Rac1 and Cdc42 from cell lysates, followed by immunoblot analysis with antiRac1 and anti-Cdc42. Stimulation with CpG resulted in similar Rac1 activation in EBV-B cells from normal and DOCK8-deficient subjects ( Fig. 3g) but caused no detectable activation of Cdc42 (data not shown). Thus, CpG activated Rac1 in B cells, but DOCK8 was not essential for this activation.
DOCK8-dependent activation of STAT3 by CpG in B cells
STAT3 is important for B cell proliferation and differentiation in response to anti-CD40 plus IL-21 (ref. 35, 36) . The stimulation of normal PBMCs with CpG induced phosphorylation of STAT3 at Tyr705 (Fig. 4a) . In contrast, CpG-driven phosphorylation of STAT3 was defective in DOCK8-deficient PBMCs, but that driven by IL-21 was not (Fig. 4a) . Phosphorylation of STAT3 driven by CpG was defective in purified DOCK8-deficient B cells, but that induced by IFN-α was not (Fig. 4b) , which indicated that the defect was B cell autonomous. IL-6 and IL-21 caused similar phosphorylation of STAT3 in purified B cells from patients and controls (Fig. 4c) . Densitometryscanning analysis demonstrated that CpG-driven phosphorylation of STAT3 in B cells from DOCK8-deficient patients was 18% ± 7% that of cells from controls, whereas IL-21-driven phosphorylation of STAT3 was similar in these cells (Fig. 4d) . The defect in CpG-driven phosphorylation of STAT3 in DOCK8-deficient B cells was not secondary to the lack of memory B cells, because CpG caused similar phosphorylation of STAT3 in purified naive B cells and unfractionated B cells from normal controls (Fig. 4e) . These results demonstrated that DOCK8 deficiency selectively impaired CpG-driven phosphorylation of STAT3 in B cells.
We investigated the role of STAT3 in the CpG-driven proliferation and differentiation of B cells by examining PBMCs from six patients with autosomal dominant hyper-IgE syndrome (AD-HIES) resulting from different dominant-negative mutations of STAT3 (Supplementary Table 3) . PBMCs from these patients had significantly impaired proliferation and IgG secretion after stimulation with CpG (Fig. 4f) . There was no significant difference between PBMCs from patients with AD-HIES and those from controls in their ability to proliferate and secrete IgE in response to anti-CD40 plus IL-4 ( Fig. 4g) . As reported before 35 , PBMCs from patients Fig. 5 ). Because IL-6 caused phosphorylation of STAT3 in DOCK8-deficient B cells, we examined whether exogenous IL-6 corrected their defective response to CpG. The addition of recombinant IL-6 to DOCK8-deficient PBMCs did not correct their defective proliferation or IgG secretion in response to CpG (Fig. 4h and data not shown) . These results indicated that in addition to the phosphorylation of STAT3, other signals important for CpG-driven proliferation and differentiation were impaired in DOCK8-deficient B cells.
The expression of TLR9 protein was similar in B cells from patients and controls (Supplementary Fig. 6a ). Correct subcellular localization of TLR9 is essential for its function 37 . Lack of DOCK8 might result in mislocalization of TLR9, which could interfere with the ability of TLR9 to activate STAT3. We stimulated EBV-B cells from normal subjects and DOCK8-deficient patients for 90 min with CpG, made them permeable and simultaneously stained for TLR9 and the endoplasmic reticulum, the early endosomal marker EEA1 or the late endosomal-lysosomal marker LAMP-1 (CD107a). Fluorescence microscopy showed that the subcellular localization of TLR9 was similar in normal and DOCK8-deficient EBV-B cells ( Supplementary  Fig. 6b ). Thus, DOCK8 had no detectable role in TLR9 trafficking in B cells.
Syk is downstream of DOCK8 in CpG-activated B cells
The tyrosine kinase Syk activates STAT3 in B lymphoma cells 38, 39 . Stimulation of normal PBMCs with CpG resulted in phosphorylation of Syk on residue Tyr352, the target of kinases of the Src family (collectively called 'Src' here; Fig. 5a ). In contrast, it caused negligible phosphorylation of Syk in DOCK8-deficient PBMCs (Fig. 5a) . The defect in phosphorylation of Syk was specific to CpG, because crosslinking of the B cell antigen receptor (BCR) with anti-IgM caused similar phosphorylation of Syk in cells from patients and those from controls (Fig. 5b) . Densitometry-scanning analysis demonstrated that CpG-driven phosphorylation of Syk in PBMCs from DOCK8-deficient patients was 16% ± 8% that of controls, whereas BCRdriven phosphorylation of Syk was not significantly different in these cells (Fig. 5c) .
We used the pentapeptide Syk inhibitor SYKINH-61 to determine whether Syk activation is important for the CpG-driven phosphorylation of STAT3. SYKINH-61 inhibited CpG-driven phosphorylation of STAT3 in normal PBMCs (85% ± 5% inhibition) but had no effect on IL-21-driven phosphorylation of STAT3 (Fig. 5d) or CpG-driven phosphorylation of p38 (data not shown). Moreover, SYKINH-61 inhibited the proliferation and IgG production driven by CpG in normal PBMCs in a dose-dependent manner but had no effect on the proliferation and IgG production driven by CD40 and IL-21 (Fig. 5e,f) .
We verified the role of Syk in CpG-driven phosphorylation of STAT3 by RNA-mediated silencing. The mouse B cell line CH12 faithfully reproduced the response of primary human B cells to CpG stimulation by showing phosphorylation of Pyk2, Syk and STAT3 (Supplementary Fig. 7a) . Treatment of CH12 cells with short hairpin RNA targeting Syk resulted in much lower expression of Syk protein and considerably inhibited the CpG-driven phosphorylation of STAT3, but the introduction of nonsilencing short hairpin RNA did not (Supplementary Fig. 7b-d) . These results placed Syk upstream of the activation of STAT3 by CpG in B cells.
CpG may bind to sensors other than TLR9 (ref. 34) . To determine if the DOCK8-dependent CpG-driven phosphorylation of Syk and STAT3 proceeded through the engagement of TLR9 and its adaptor MyD88, we compared the responses of purified splenic B cells (Fig. 5g,h Fig. 8 ). Together these results indicated that CpG ODN 1826 engaged TLR9-MyD88 to cause DOCK8-dependent phosphorylation of Syk and STAT3, which was essential for the proliferation and differentiation of B cells.
CpG activates a Pyk2-Src-Syk-STAT3 cascade in B cells
Stimulation of normal PBMCs with CpG resulted in the tyrosine phosphorylation of proteins with molecular weights that corresponded to those of Src (54-56 kilodaltons (kDa)), the Src target Syk (72 kDa) and Pyk2 (110 kDa), a tyrosine kinase that functionally interacts with Src (Fig. 6a) . In contrast, it caused minimal protein tyrosine phosphorylation in PBMCs from DOCK8-deficient patients. This defect was selective to stimulation with CpG, because crosslinkage of the BCR caused similar tyrosine phosphorylation in PBMCs from DOCK8-deficient patients and those from controls (data not shown), consistent with the normal activation of B cells from DOCK8-mutant mice after crosslinkage of the BCR 22 . Pyk2 is autophosphorylated on Tyr402 (ref. 40) . Activated Src is autophosphorylated on tyrosine residues that correspond to Tyr416 in Src 40 and is recognized by antibody to Src phosphorylated at Tyr416. Immunoblot analysis of lysates of PBMCs with a phosphorylationspecific monoclonal antibody to Pyk2 phosphorylated at Tyr402 and to Src phosphorylated at Tyr416 demonstrated that stimulation with CpG caused phosphorylation of Pyk2 and Src in normal PBMCs (Fig. 6b) . In contrast, stimulation with CpG caused minimal phosphorylation of Pyk2 and Src in DOCK8-deficient PBMCs (Fig. 6b) , which demonstrated that CpG-driven tyrosine phosphorylation of Pyk2 and Src was DOCK8 dependent. Pyk2 and Src were phosphorylated after CpG stimulation of B cells from wild-type mice but not those from Myd88 −/− mice (Fig. 6c) , which indicated that TLR9-driven phosphorylation of Pyk2 and Src, like that of Syk and STAT3, was dependent on MyD88.
We used selective inhibitors of Pyk2 and Src to examine the roles of these kinases in the CpG-driven activation of B cells. The Pyk2 inhibitor tyrphostin A9 considerably inhibited the CpG-driven tyrosine phosphorylation of Pyk2 (84% ± 3%), Src (81% ± 6%), Syk (95% ± 4%) and STAT3 (97% ± 2%; Fig. 6d-g ). Tyrphostin A9 had no detectable effect on the IL-6-driven phosphorylation of STAT3 or CpG-driven phosphorylation of p38 (data not shown). Tyrphostin A9 considerably inhibited the secretion of IgG driven by CpG (90% ± 2%) but not that driven by CD40 and IL-21 (Fig. 6h) . We obtained similar results with the structurally different Pyk2 inhibitor PF562271 (data not shown). We verified the role of Pyk2 in the CpG-driven phosphorylation of STAT3 in CH12 B cells through the knockdown of Pyk2 with short hairpin RNA (Supplementary Fig. 7b-d) .
The Src inhibitor PP2 had a modest effect on the inhibition of CpGdriven phosphorylation of Pyk2 (28% ± 13%; Fig. 6d ) but had a much greater effect on the inhibition of CpG-driven phosphorylation of Src (80% ± 8%), Syk (71% ± 9%) and STAT3 (63% ± 11%; Fig. 6e-g ). The modest inhibition of Pyk2 phosphorylation was consistent with the ability of Src to activate Pyk2 (ref. 40 ) and suggested feedback amplification of the activation of Pyk2 by Src. The less-than-complete inhibition of Syk and phosphorylation of STAT3 could have been due to the ~20% residual Src activity. Alternatively, a Src-independent link between Pyk2 and Syk-STAT3 might exist. PP2 inhibited the secretion of IgG driven by CpG (70% ± 12%) but had no effect on IgG secretion driven by CD40 and IL-21 (Fig. 6h) . We obtained similar results with the structurally different Src kinase inhibitor SU6656 (data not shown). Together these results suggested that ligation of TLR9 activated a Pyk2-Src-Syk cascade that resulted in the phosphorylation of STAT3.
A DOCK8-MyD88-Pyk2 complex links to Lyn Our results placed DOCK8 and Pyk2 downstream of MyD88. To determine whether DOCK8 associates with MyD88, we transfected 293T human embryonic kidney cells with vectors encoding Myc-tagged DOCK8 and either hemagglutinin-tagged MyD88 or hemagglutinin-tagged MRTF-A (myocardin-related transcription factor A; control). DOCK8 precipitated together with MyD88 but not with MRTF-A (Fig. 7a) . To determine whether DOCK8 associated with MyD88 in B cells, we immunoprecipitated proteins from normal EBV-B cells with anti-DOCK8 and probed for MyD88. DOCK8 associated weakly with MyD88 in unstimulated cells but this association increased after stimulation with CpG (Fig. 7b) .
Pyk2 is reported to interact with MyD88 in macrophages 41 . This interaction has been mapped to the proline-rich carboxy-terminal region of Pyk2 and the death domain of MyD88. When we immunoprecipitated proteins from normal EBV-B cells with anti-MyD88 and probed the immunoprecipitates with monoclonal antibody to Pyk2, we found that Pyk2 associated with MyD88 (Fig. 7c) . This association was not altered detectably by stimulation with CpG and was independent of DOCK8, as Pyk2 precipitated together with MyD88 from lysates of EBV-B cells from DOCK8-deficient patients (Fig. 7c) . We readily detected Pyk2 among proteins immunoprecipitated from (Fig. 7d) . The constitutive association of DOCK8 and Pyk2 was independent of MyD88 and was present in EBV-B cells from a MyD88-deficient patient that had no detectable expression of MyD88 protein (Fig. 7d) . However, stimulation with CpG did not increase the association of DOCK8 and Pyk2 in the absence of MyD88. These results suggested that DOCK8 formed a complex with MyD88 and Pyk2.
The Tyr-Glu-Glu-Val-Lys motif (amino acids 628-632) in the DHR-1 domain of DOCK8 also exists in cofilin-1, in which it is a target of Pyk2 phosphorylation 42 . This motif is located in a sequence in DOCK8 (HNKSPDFYEEVKIKL; amino acids 621-635) that is a potential binding site for the Src-homology 2 domain of Src. Probing DOCK8 immunoprecipitates from EBV-B cells with monoclonal antibody to phosphorylated tyrosine and to Src showed that stimulation with CpG caused tyrosine phosphorylation of DOCK8 and its association with Src (Fig. 7e) . Both events were abrogated by the Pyk2 inhibitor tyrphostin A9. The Src Lyn is expressed 'preferentially' in B cells 43 . When we immunoprecipitated proteins with anti-Lyn and probed the immunoprecipitates with a monoclonal antibody to Src phosphorylated at Tyr416, we found that stimulation with CpG caused tyrosine phosphorylation of Lyn in normal B cells (Fig. 7f) . Furthermore, stimulation with CpG resulted in robust association of Lyn with DOCK8, which was abrogated by the addition of tyrphostin A9 (Fig. 7g) . These results indicated that ligation of TLR9 in B cells resulted in Pyk2-dependent phosphorylation of DOCK8 and recruitment of Src and/or Lyn.
DISCUSSION
We have presented evidence here that DOCK8 functioned as an adaptor that linked TLR9 via MyD88 to a Pyk2-Src-Syk-STAT3 signaling cascade, and we have demonstrated that this pathway was essential for TLR9-driven B cell proliferation and immunoglobulin production. DOCK8-deficient patients had impaired ability to sustain a protective antibody response, similar to DOCK8-mutant mice, and lacked circulating CD27 + memory B cells. DOCK8-deficient B cells did not proliferate or secrete IgM or IgG in response to CpG. This defect was cell autonomous, was specific to CpG and was not accounted for by the lack of memory B cells. Because of constraints in obtaining sufficient amounts of blood from children for B cell purification, we used PBMCs, which we stimulated with the B cell-selective TLR9 ligand CpG, and/or EBV-B cells. Whenever possible, we also used purified B cells from at least two patients.
Stimulation with CpG upregulated the expression of AICDA, CD23 and CD86 normally in DOCK8-deficient B cells and resulted in normal activation of NF-κB and p38 and normal IRF7-dependent secretion of IFN-α in DOCK8-deficient PBMCs, which indicated that these events occurred independently of DOCK8. Unexpectedly, given the reported guanine nucleotide-exchange activity of DOCK proteins for small GTPases 21 , CpG activated Rac1 independently of DOCK8. The activation of Rac1 by CpG in pDCs uses a non-TLR9 sensor and DOCK2 (ref. 34) . A similar pathway could be operative in B cells.
A central finding of our study was that CpG caused phosphorylation of STAT3 in B cells in a DOCK8-dependent manner. Impaired phosphorylation of STAT3 in DOCK8-deficient B cells was specific to stimulation with CpG and was not secondary to the lack of memory B cells. A critical role for STAT3 in CpG-driven proliferation and differentiation of B cells was demonstrated by the observation that these responses were impaired in patients with dominant-negative mutations in STAT3. The inability of IL-6, which caused phosphorylation of STAT3 in DOCK8-deficient B cells, to correct their defective response to CpG indicated that other DOCK8-dependent signals were also required for CpG-driven B cell proliferation and IgG secretion. These may include signals delivered by Pyk2, Src and Syk, which trigger activation of phospholipase C-γ, phosphatidylinositol-3-OH kinase and the B cell linker BLNK [44] [45] [46] .
We found that Syk had a critical role in the CpG-driven, STAT3-dependent proliferation and differentiation of B cells. Stimulation of B cells with CpG resulted in the phosphorylation of Syk, which was considerably impaired in DOCK8-deficient B cells; this placed Syk downstream of DOCK8. The Syk-selective inhibitor SYKINH-61 blocked CpG-driven phosphorylation of STAT3, which placed Syk 
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upstream of STAT3, and inhibited CpG-driven B cell proliferation and IgG secretion. Stimulation of B cells with CpG resulted in DOCK8-dependent phosphorylation of Pyk2 and Src. We demonstrated that DOCK8 linked TLR9-MyD88 to a Pyk2-Src-Syk-STAT3 cascade in B cells, which we found was essential for the TLR9-driven activation of B cells. The observation that CpG-driven phosphorylation of Pyk2, Src, Syk and STAT3, as well as B cell proliferation and differentiation, were dependent on TLR9 and MyD88 indicated that engagement of TLR9-MyD88 by CpG resulted in DOCK8-dependent activation of B cells. CpG type A DNA has been reported to induce the tyrosine phosphorylation of proteins, including Syk, in monocytes and macrophages independently of TLR9 and MyD88 (ref. 47) . Differences between that study 47 and our study here in the oligodeoxynucleotides and target cells used may account for the difference noted in the requirement for TLR9 and MyD88.
We found DOCK8 existed in a complex with MyD88 and Pyk2. MyD88 was not essential for the DOCK8-Pyk2 association, and DOCK8 was not essential for the MyD88-Pyk2 association, although it was essential for the phosphorylation of Pyk2 after TLR9 ligation. After stimulation with CpG, DOCK8 became more strongly associated with MyD88 and Pyk2, underwent tyrosine phosphorylation and associated with Src and/or Lyn. We propose the following model of DOCK8-dependent TLR9 signaling. Ligation of TLR9 by CpG causes recruitment and stabilization of a preexisting MyD88-Pyk2-DOCK8 complex, which results in the autophosphorylation and activation of Pyk2. Pyk2 then phosphorylates DOCK8, causing it to recruit Src kinases, including Lyn, via their Src-homology 2 domain, which releases them from autoinhibition. Src then activates Syk, which drives STAT3 activation. Our proposed pathway is probably a simplification. Src and Syk can phosphorylate Pyk2 (ref. 40) , and Src and Pyk2 can act in synergy to cause STAT3 phosphorylation 48, 49 . Future experiments should determine whether the DOCK8-dependent TLR9-MyD88 signaling pathway we have identified is used by other receptors that signal via MyD88 in B cells and other cells. Preliminary data have indicated that this pathway is activated by TLR4 ligation in PBMCs (data not shown).
DOCK8 deficiency results in impaired immunological synapses in B cells 22 and may impair the ability of T cells and dendritic cells to drive antibody production by B cells. Mice with selective DOCK8 deficiency in B cells, as well as mice in which the interaction between MyD88 and DOCK8 is disrupted, will help define the contribution of DOCK8-dependent MyD88 signaling in B cells to the impaired serological memory of DOCK8 deficiency. Given that TLR9 ligands are vaccine adjuvants and given the role of TLR9 in autoantibody responses to self DNA 50 , the TLR9 signaling pathway we have described may be important for the development of better vaccines and the understanding and treatment of autoantibody-mediated diseases.
METHODS
Methods and any associated references are available in the online version of the paper.
